Is Alpha Cognition Inc (ACOG) a Buy, Sell, or Hold?
Alpha Cognition Inc
NASDAQ:ACOG
$8.05 USD
-$0.33 (-3.94%)
- Volume
- 133.56K
- Average Volume
- 42.72K
- Market Capitalization
- $125.03M
- P/E Ratio
- -6.00
- Dividend Yield
- 0.00%
- Price Target
- $14.00
- Year High
- $10.65
- Year Low
- $4.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.64
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael E. McFadden |
| Industry | Financial - Conglomerates |
| Sector | Financial Services |
| Current Symbol | ACOG |
| CUSIP | 02074J501 |
| CIK | 0001655923 |
| Web | https://www.alphacognition.com |
| Phone | 858 344 4375 |
| Currency | USD |
| Employees | 71 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 12.64 |
| Quick Ratio | 11.52 |
| Cash Ratio | 10.00 |
Sales & Book Value
| Annual Sales | $10.22M |
| Price / Sales | 11.55 |
| Cash Flow | -1.40 |
| Price / Cash Flow | -4.11 |
| Price / Book | 3.05 |
Price Target and Rating
| Average Stock Price Forecast | $14.00 |
| High Stock Price Forecast | $20.00 |
| Low Stock Price Forecast | $12.00 |
| Forecast Upside/Downside | -42.50% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.17 |
| Trailing P/E Ratio | -6.00 |
| PEG Ratio | 0.43 |
| P/E Growth | 0.43 |
| Net Income | $-20.67M |
| Net Margin | -232.24% |
| Pretax Margin | -232.24% |
| Return on Equity | -54.13% |
| Return on Assets | -36.31% |
Financials Score
| AltmanZ Score | 7.27 |
| Piotroski Score | 2.00 |
| Working Capital | 63.13M |
| Total Assets | 69.25M |
| Ebit | -27.06M |
| Market Cap | 184.83M |
| Total Liabilities | 11.79M |
Poll Results
About Alpha Cognition Inc (NASDAQ:ACOG) Stock
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The comp ... any was founded in 2000 and is headquartered in Vancouver, Canada.
2026-07-10 08:30:00
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachu.
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
2026-06-23 09:00:00
Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, or the âCompanyâ), a biopharmaceutical company focused on developing novel therapies for debili
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
2026-06-23 08:30:00
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. “On behalf of the entire Board of Directors, we are.
2026-06-16 08:30:00
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (ACOG: NASDAQ) (“Alpha Cognition” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. RESOLVE is a mult.
2026-06-09 08:00:00
Alpha Cognition Inc. (NASDAQ: ACOG) (âAlpha Cognitionâ, âACIâ, or the âCompanyâ), a biopharmaceutical company developing novel therapeutics for deb
2026-06-09 08:00:00
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced the top-line results from its BEACON real-world study evaluating provider-reported cognitive, behavioral, functional, and tolerability outcomes among long-term care residents with mild to moderate Alzheimer's disease who were receiv.
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call Transcript
2026-05-15 16:10:43
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Tops Revenue Estimates
2026-05-14 18:50:21
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.2 per share a year ago.
Frequently Asked Questions
-
What is the current Alpha Cognition Inc (ACOG) stock price?
-
Alpha Cognition Inc(NASDAQ:ACOG) stock price is $8.05 in the last trading session. During the trading session, ACOG stock reached the peak price of $10.65 while $4.5 was the lowest point it dropped to. The percentage change in ACOG stock occurred in the recent session was --3.94% while the dollar amount for the price change in ACOG stock was -$-0.33.
-
ACOG's industry and sector of operation?
-
The NASDAQ listed ACOG is part of Financial - Conglomerates industry that operates in the broader Financial Services sector.
-
Who are the executives of ACOG?
-
Henry Du | Vice President of Finance & Accounting and Interim Chief Financial Officer
Kenneth Anthony Cawkell | Founder, Consultant, Corporate Secretary & Director
Christine Reveal | Vice President of Marketing & Commercial Strategy
Michael E. McFadden | Chief Executive Officer & Director
Timothy Ayers | Head of Compliance -
How many employees does ACOG have?
-
Number of ACOG employees currently stands at 71. ACOG operates from 750 West Pender Street, Grapevine, TX V6C 2T8, US.
-
Link for ACOG official website?
-
Official Website of ACOG is: https://www.alphacognition.com
-
How do I contact ACOG?
-
ACOG could be contacted at phone #858 344 4375 and can also be accessed through its website. ACOG operates from 750 West Pender Street, Grapevine, TX V6C 2T8, US.
-
How many shares of ACOG are traded daily?
-
The average number of ACOG shares traded daily for last 3 months was 42.72K.
-
What is the market cap of ACOG currently?
-
The market value of ACOG currently stands at $125.03M with its latest stock price at $8.05